Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseTransplantation, AutologousPeripheral Blood Stem Cell TransplantationMyeloablative AgonistsStem CellsHematologic NeoplasmsTransplantation ChimeraBone Marrow TransplantationTreatment OutcomeBusulfanTissue DonorsReceptors, CXCR4Graft vs Leukemia EffectRemission InductionRecurrenceVidarabineGraft SurvivalCord Blood Stem Cell TransplantationHistocompatibility TestingHematopoietic Stem CellsLiver TransplantationWhole-Body IrradiationGraft vs Tumor EffectCombined Modality TherapyMultiple MyelomaImmunosuppressive AgentsRetrospective StudiesLeukemiaLeukemia, Myeloid, AcuteMesenchymal Stem Cell TransplantationMelphalanLymphocyte TransfusionDisease-Free SurvivalSiblingsHistocompatibilitySurvival AnalysisSalvage TherapySurvival RateMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell TransplantationHematopoietic Stem Cell MobilizationCytomegalovirus InfectionsAntilymphocyte SerumKidney TransplantationLymphocyte DepletionHepatic Veno-Occlusive DiseaseEmbryonic Stem CellsCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsChimerismPrecursor Cell Lymphoblastic Leukemia-LymphomaMinor Histocompatibility AntigensTime FactorsNeoplasm, ResidualAdult Stem CellsVirus ActivationAntigens, CD34HLA AntigensHematologic DiseasesFollow-Up StudiesAcute DiseaseTransplantation ImmunologyT-LymphocytesReceptors, CXCR3PrognosisAnemia, AplasticCytomegalovirusHeart TransplantationLymphoma, Non-HodgkinGraft RejectionCytarabineCell DifferentiationPluripotent Stem CellsGranulocyte Colony-Stimulating FactorImmunosuppressionHodgkin DiseaseTransplantation, IsogeneicLung TransplantationAntineoplastic AgentsStem Cell NichePrimary MyelofibrosisNeural Stem CellsLeukemia, MyeloidMesenchymal Stromal CellsInfectionAntibodies, NeoplasmImmunocompromised HostEtoposideLymphoproliferative DisordersCyclosporineBone Marrow CellsUnrelated DonorsLiving DonorsFlow CytometryRoseolovirus Infections